以岭药业
(002603)
| 流通市值：206.72亿 | | | 总市值：250.94亿 |
| 流通股本：13.76亿 | | | 总股本：16.71亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,074,750,595 | 2,439,783,832.76 | 7,830,737,438.74 | 5,867,603,073.61 |
| 营业收入 | 4,074,750,595 | 2,439,783,832.76 | 7,830,737,438.74 | 5,867,603,073.61 |
| 二、营业总成本 | 3,172,624,664.1 | 1,941,982,482.08 | 6,149,554,601.93 | 4,704,006,732.64 |
| 营业成本 | 1,507,910,269.01 | 974,597,489.87 | 2,797,410,173.75 | 2,315,869,844.22 |
| 税金及附加 | 73,911,339.52 | 42,445,094.34 | 135,973,295.9 | 94,880,945.65 |
| 销售费用 | 1,058,642,073.76 | 632,743,970.49 | 1,964,277,744.97 | 1,352,967,439.64 |
| 管理费用 | 229,028,119.2 | 116,624,123.88 | 535,049,702.02 | 398,090,659.13 |
| 研发费用 | 299,891,489.94 | 173,790,844.78 | 718,253,979.75 | 544,012,861.24 |
| 财务费用 | 3,241,372.67 | 1,780,958.72 | -1,410,294.46 | -1,815,017.24 |
| 其中:利息费用 | 574,295.7 | 361,449.71 | 1,063,403.55 | 760,671.95 |
| 其中:利息收入 | 1,206,405.07 | 724,968.11 | 6,514,643.47 | 5,256,531.37 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 370,808.2 | 848,412.44 | 3,922,789.94 | - |
| 加:投资收益 | 11,461,045.38 | 4,348,752.35 | 2,074,403.4 | -113,080.5 |
| 资产处置收益 | -362,766.93 | -51,857.65 | -887,249.18 | -358,873.93 |
| 资产减值损失(新) | -16,105,117.19 | -3,524,946.85 | -148,272,874.94 | -37,735,638.42 |
| 信用减值损失(新) | -5,579,098.7 | -7,340,471.72 | -11,958,411.74 | 5,032,693.38 |
| 其他收益 | 24,414,599.68 | 7,660,027.5 | 97,369,978.46 | 56,884,631.1 |
| 四、营业利润 | 916,325,401.34 | 499,741,266.75 | 1,623,431,472.75 | 1,187,306,072.6 |
| 加:营业外收入 | 2,482,532.26 | 866,316.54 | 11,755,718.44 | 10,772,771.7 |
| 减:营业外支出 | 7,438,376.32 | 11,508,303.99 | 43,576,289.11 | 28,443,444.08 |
| 五、利润总额 | 911,369,557.28 | 489,099,279.3 | 1,591,610,902.08 | 1,169,635,400.22 |
| 减:所得税费用 | 154,292,458.3 | 80,486,850.1 | 309,880,994.2 | 172,961,064.32 |
| 六、净利润 | 757,077,098.98 | 408,612,429.2 | 1,281,729,907.88 | 996,674,335.9 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 757,077,098.98 | 408,612,429.2 | 1,281,729,907.88 | 996,674,335.9 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 757,298,017.44 | 408,848,309.57 | 1,286,478,662.67 | 1,000,404,671.91 |
| 少数股东损益 | -220,918.46 | -235,880.37 | -4,748,754.79 | -3,730,336.01 |
| 扣除非经常损益后的净利润 | 731,053,707.57 | 406,950,828.35 | 1,221,723,222.61 | 966,453,850.25 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.45 | 0.24 | 0.77 | 0.6 |
| (二)稀释每股收益 | 0.45 | 0.24 | 0.77 | 0.6 |
| 八、其他综合收益 | -299,714.12 | 382,786.36 | -713,938 | 96,367.62 |
| 归属于母公司股东的其他综合收益 | -299,714.12 | 382,786.36 | -713,938 | 96,367.62 |
| 九、综合收益总额 | 756,777,384.86 | 408,995,215.56 | 1,281,015,969.88 | 996,770,703.52 |
| 归属于母公司股东的综合收益总额 | 756,998,303.32 | 409,231,095.93 | 1,285,764,724.67 | 1,000,501,039.53 |
| 归属于少数股东的综合收益总额 | -220,918.46 | -235,880.37 | -4,748,754.79 | -3,730,336.01 |
| 公告日期 | 2026-08-29 | 2026-04-28 | 2026-04-28 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |